Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New insulin pen aims to make diabetes shots easier

NCT ID NCT07052292

Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how easy and convenient the DuraTouch® device is for injecting insulin. 128 people with type 1 or type 2 diabetes used the device for 12 weeks and rated their satisfaction. The goal was to see if the device improves the daily injection experience.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DuraTouch® insulin injection device
What this could lead to
If successful, this could confirm that DuraTouch® is easy and convenient for daily insulin injections, improving the user experience for people with diabetes.
What could go wrong
This is a small, completed post-market study focused on user feedback, not on blood sugar control or long-term health outcomes. Results may not apply to all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

128 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population included participants with Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) who require insulin injection.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The decision to initiate treatment with DuraTouch® has been made by the participant/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study. * All needed signed consent(s) are obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Mental incapacity (when no caregiver and LAR are assigned to the patient), unwillingness or language barriers precluding adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Diabetes mellitus, type 1

Contacts and locations

Locations

  • "Santa Familia PTG tódz

    Lodz, Pomeranian Voivodeship, 90-302, Poland

  • CenterMed Krakow Sp. z o.o.

    Krakow, Lesser Poland Voivodeship, 31-530, Poland

  • Centrum Medyczne Ekamed sp. z o.o.

    Lublin, Lublin Voivodeship, 20-718, Poland

  • Diab Serwis POPENDA Spólka Jawna

    Chorzów, Silesian Voivodeship, 41-500, Poland

  • Diabetica sp. z o.o.

    Nysa, Opole Voivodeship, 48-300, Poland

  • Diabetolog praktyka lekarska - Bartosz Bednarkiewicz

    Lubin, Lower Silesian Voivodeship, 59-300, Poland

  • Gabinet Lekarski Internistyczny Iwona Towpik

    Zielona Góra, Lubusz Voivodeship, 65-034, Poland

  • Ginemedica Sp. z o.o. Sp.k

    Wroclaw, Kuyavian-Pomeranian Voivodeship, 50-414, Poland

  • NZOZ Gdanska Poradnia Cukrzycowa Sp. z o.o

    Gdansk, Pomeranian Voivodeship, 80-858, Poland

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji - Klinika Chorob Wewnetrznych, Endokrynologii i Diab

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Poradnia Diabetologiczna. Niepubliczny Zaklad Opieki Zdrowotnej Lege Artis

    Bialystok, Podlaskie Voivodeship, 15-404, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.